// Junyi He 1, * , Sheng Shen 1, * , Weiqi Lu 1, * , Yuhong Zhou 2 , Yingyong Hou 3 , Yong Zhang 1 , Ying Jiang 1 , Houbao Liu 1 , Yebo Shao 1 1 Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China 2 Department of Clinical Oncology, Zhongshan Hospital, Fudan University, Shanghai 200032, China 3 Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai 200032, China * These authors have contributed equally to this work Correspondence to: Houbao Liu, email: liuhbzsht@163.com Yebo Shao, email: shao.yebo@zs-hospital.sh.cn Keywords: histone deacetylase 1 (HDAC1), TCF-12, migration, invasion, GBC Received: December 23, 2015 Accepted: March 28, 2016 Published: April 15, 2016 ABSTRACT The identification of prognostic markers for gallbladder cancer is needed for clinical practice. Histone deacetylases (HDACs) play an important role in tumor development and progression by modifying histone and non-histone proteins. However, the expression of HDAC1 in patients with gallbladder cancer is still unknown. Here, we reported that HDAC1 expression was elevated in cancerous tissue and correlated with lymph node metastasis and poorer overall survival in patients with GBC. Knockdown of HDAC1 using lentivirus delivery of HDAC1-specific shRNA abrogated the migration and invasion of GBC cells in vitro . TCF-12, as the HDAC1 binding protein, has also correlates with poor prognosis in GBC patients. And there is a positive correlation between HDAC1 and TCF-12 which leading the high invasion and migration ability of GBC cells. Taken together, our data suggested that HDAC1 and TCF-12 are a potential prognostic maker and may be a molecular target for inhibiting invasion and metastasis in GBC.
No takes yet. Share an insight, caveat, or question.
He et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: